Plasma Biomarkers and Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer: New Tools for Better Patient Selection?

Plasma Biomarkers and Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer: New Tools for Better Patient Selection?

Immune checkpoint inhibitors (ICIs) have transformed the treatment landscape for patients with non-small cell lung cancer (NSCLC). Although some patients can experience important response rates and improved survival, many others do not benefit from ICIs developing hyper-progressive disease or immune...

Full description

Bibliographic Details
Main Authors: Adrien Costantini, Paul Takam Kamga, Coraline Dumenil, Thierry Chinet, Jean-François Emile, Etienne Giroux Leprieur
Format: Article
Language:English
Published: MDPI AG 2019-08-01
Series:Cancers
Subjects:
non-small cell lung cancer
plasma
biomarkers
immune checkpoint inhibitor
Online Access:https://www.mdpi.com/2072-6694/11/9/1269

Internet

https://www.mdpi.com/2072-6694/11/9/1269

Similar Items